Ozzy Osbourne: I was convinced I was dying during nightmare health year – Kokomo Perspective

Ozzy Osbourne was "convinced" he was dying amid his year plagued with health setbacks.

The 'Crazy Train' hitmaker suffered a nightmare year in 2019 which saw him endure several medical issues including a fall, neck surgery, an infection in his hand, and hospitalization for the flu.

And at the start of 2020, he revealed he had been diagnosed with Parkinson's - which is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination - for which he later had stem cell treatment to try and ease the symptoms.

Discussing his year of ill health, Ozzy said: "I'm not back to 100 percent. I'm about 75 percent there, but it's such a slow recovery. Spine surgery is bad news, man. I've been in such a bad state with pain; I'm still having a lot of pain.

"There was a point I was convinced that I was dying. I was in that much discomfort and pain and misery. I thought they were all hiding it from me. I remember saying to Sharon, 'You've gotta level with me. Is it worse than you're making it out [to be]?' She says, 'No.' ... I've dropped all the medication for pain now."

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free. Please support us by making a contribution.

And despite his health woes, the 71-year-old rocker is itching to get back on stage as soon as the coronavirus pandemic - which has forced all concerts to be cancelled - has passed.

He added in an interview for SiriusXM: "I cannot wait [to get on stage], but I was talking to Tony Iommi the other day, and he was saying with the way it's going with this coronavirus, indoor shows will be a thing of the past."

Meanwhile, Ozzy's daughter Kelly Osbourne said earlier this year her dad is beginning to feel much better, following a "treatment of stem cell".

She explained: "Seeing after one treatment of stem cell what has happened and the progress that he's made is mind blowing. He wants to get up. He wants to do things. He wants to be part of the world again. He's walking better. He's talking better. His symptoms are lessening. He is building the muscle strength back that he needs after his spine surgery."

Follow this link:
Ozzy Osbourne: I was convinced I was dying during nightmare health year - Kokomo Perspective

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with…

July 31, 2020 15:38 ET | Source: Genmab A/S

Company Announcement

Copenhagen, Denmark; July 31, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC (Janssen) reported positive results from the Phase 3 APOLLO (MMY3013) study of the subcutaneous (SC) formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide (an immunomodulatory drug) and a proteasome inhibitor (PI). The study met the primary endpoint of improving progression-free survival (PFS). Overall, the safety profile of daratumumab SC in combination with Pd was consistent with the safety profile for each therapy separately.

We are pleased with these positive results for daratumumab, administered as a subcutaneous formulation, in combination with pomalidomide and dexamethasone. The corresponding intravenous regimen was previously approved by the U.S. FDA based on the Phase1 single-arm EQUULEUS study, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Janssen Biotech, Inc., which obtained an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab in 2012, intends to discuss the data with health authorities in preparation for regulatory submissions and plans to submit the data for presentation at an upcoming medical conference.

The APOLLO study was designed to confirm the results from the Phase 1 EQUULEUS (MMY1001) study, which investigated intravenous (IV) daratumumab plus Pd in the same indication. In June 2017, the U.S. Food and Drug Administration (U.S. FDA) approved the use of DARZALEX in combination with Pd for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and aPI based on the results of the EQUULEUS study.

About the APOLLO (MMY3013) study This Phase 3 (NCT03180736), randomized, open-label, multicenter study included 304 patients with multiple myeloma who have previously been treated with lenalidomide and a PI. Patients were randomized 1:1 to either receive daratumumab in combination with Pd or Pd alone. In the original design of the study, patients in the daratumumab plus Pd arm were treated with the IV formulation of daratumumab. As of Amendment 1, all new subjects in the experimental arm were dosed with the SC formulation of daratumumab and patients who had already begun treatment with IV daratumumab had the option to switch to the SC formulation. The primary endpoint of the study was PFS. The study was conducted in Europe under an agreement between Janssen, EMN and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON).

About multiple myelomaMultiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.2 Approximately 26,000 new patients were estimated diagnosed with multiple myeloma and approximately 13,650 people were expected to have died from the disease in the U.S. in 2018.3 Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.4 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.5

About DARZALEX(daratumumab) DARZALEX (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy7. Daratumumab is the first subcutaneous CD38-directed antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.8 DARZALEX FASPRO is the first subcutaneous CD38-directed antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,9,10,11,12

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV. TEPEZZA is a trademark of Horizon Therapeutics plc.

1 American Cancer Society. "Multiple Myeloma Overview." Available at http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma.Accessed June 2016. 2 National Cancer Institute. "A Snapshot of Myeloma." Available at http://www.cancer.gov/research/progress/snapshots/myeloma. Accessed June 2016. 3 Globocan 2018. United States of America Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/840-united-states-of-america-fact-sheets.pdf. 4 Globocan 2018. World Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 2018. 5 American Cancer Society. "How is Multiple Myeloma Diagnosed?" http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-diagnosis. Accessed June 2016 6 DARZALEX Prescribing information, September 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf Last accessed September 2019 7 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed June 2020 8 DARZALEX FASPRO Prescribing information, May 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf Last accessed May 2020 9 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848. 10 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21. 11 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94. 12 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.Blood. 2012; 120(21): abstract 2974.

Company Announcement no. 33 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark

See the original post:
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with...

COVID-19 Impact Analysis on Stem Cell Banking Industry. Insights on Strategies of Key Players Bulletin Line – Bulletin Line

One of the major factors fuelling the increasing popularity of stem cell banking is the increasing prevalence of chronic diseases such as cancer across the world. As per the World Health Organization (WHO), one of the major causes of mortality and morbidity throughout the world is cancer, with almost 14 million people getting affected by the disease in 2012. Furthermore, the number of new cancer cases is predicted to increase by 70% all around the world in the next two decades.

Download sample copy of this report: https://www.psmarketresearch.com/market-analysis/stem-cell-banking-market/report-sample

Stem cell therapies are being increasingly adopted in many countries, because of their huge success in treating cancer and other types of chronic diseases. Moreover, the rising awareness amongst the people about the need for preserving stem cells will further boost the demand for stem cell banking in future. Due to these factors, the global stem cell banking market is expected to register unprecedented growth during the forecast period (20202030). Stem cells are basically, used for generating new cells and tissues for the treatment of various diseases such as Parkinsons disease, Alzheimers disease, arthritis, diabetes, and heart diseases.

Stem cell banking is widely used for the treatment of leukemia, autism, diabetes, thalassemia, and cerebral palsy. Out of these, the prevalence of leukemia is rising at a rapid pace across the world, which is in turn, fuelling the progress of the stem cell banking market all over the world. As per the Leukemia and Lymphoma Society (LLS), which is a voluntary healthcare organization focussing on providing access to blood cancer patients for treatments and funding research activities regarding the same, one person is diagnosed with blood cancer in the U.S. at almost every 3 minutes.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=stem-cell-banking-market

This study covers

Read more here:
COVID-19 Impact Analysis on Stem Cell Banking Industry. Insights on Strategies of Key Players Bulletin Line - Bulletin Line

AlloVir raises $276M IPO to run broad cell therapy program – FierceBiotech

AlloVir has raised $276 million in an upsized IPO to fund development of allogeneic T-cell treatments for viral diseases. The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.

Massachusetts-based AlloVir generates off-the-shelf virus-specific T cells in donors before stimulating their peripheral blood mononuclear cells to selectively activate and expand the therapeutic cells. By giving patients T cells that partially match their HLA subtype, AlloVir thinks it can kill virus infected cells without harming healthy cells or causing graft-versus-host disease.

Viralym-M is the most advanced manifestation of the approach. Baylor College of Medicine has taken the treatment for five common viruses through phase 2, setting AlloVir up to push the drug toward approval while generating clinical proof-of-concept data in other indications.

AlloVir plans to spend $98 million to take Viralym-M through phase 3 trials in immunocompromised patients post allogeneic hematopoietic stem cell transplant (HSCT) who have complications linked to hemorrhagic cystitis, cytomegalovirus or adenovirus. The phase 2 linked adenovirus Viralym-M to a 93% clinical response rate in HSCT patients with one or more treatment-refractory infections.

The size of the IPO means AlloVir has enough money to pursue other opportunities. In addition to the three phase 3 trials, AlloVir plans to start three phase 2 trials to test Viralym-M in the prevention of multi-virus infections in HSCT patients, and the treatment of BK and cytomegalovirus in kidney and solid organ transplant recipients, respectively.

AlloVir has set aside $83 million for the phase 2 program, leaving it with cash to spend on two other assets. A second cell therapy, ALVR106, is due to enter the clinic in autologous and allogeneic HSCT patients with respiratory viral diseases in the fourth quarter. AlloVir has earmarked $56 million for work on ALVR106.

A further $33 million will go toward a phase 1/2 trial of AlloVirs COVID-19 prospect. AlloVir joined the race to develop a COVID-19 treatment in March, teaming up with Baylor College of Medicine to create an off-the-shelf cell therapy against SARS-CoV-2 and other coronaviruses. The resulting drug, ALVR109, is made of CD4+ and CD8+ virus-specific T cells generated from healthy donors.

Baylor filed an IND for ALVR109 in June, only for FDA to hit it with a clinical hold earlier this month amid safety concerns related to the quality of ancillary reagents unique to ALVR109. Despite the setback, AlloVir still expects the trial to get underway this year and deliver top-line data in 2021.

Read more:
AlloVir raises $276M IPO to run broad cell therapy program - FierceBiotech

What Is the Impact of COVID-19 on Cancer Stem Cells Market During Projected Period of 2020-2026? – Market Research Posts

The abrupt rise of the COVID-19 pandemic has enforced an optimistic impact on the global cancer stem cells market growth in 2020. Rising demand for treatment of metastatic stage cancer in the course of the COVID-19 pandemic is shoving the growth of the market. Analysts have predicted that the market will perceive continuous growth after the end of the COVID-19 disaster.

The latest report published by Research Dive on the global cancer stem cells reveals the impact of COVID-19 pandemic on the market growth. Before the rise of the pandemic, the market was expected to grow at a CAGR of 10.3% from 2019 to 2026. However, the sudden outburst of the COVID-19 pandemic has fueled the market growth. Our analysts have estimated that the market is expected to grow at 11.8% CAGR, post-COVID-19 upheaval. The market is anticipated to perceive growth owing to the mounting demand for increased mortality and morbidity rate of cancer during the course of the pandemic.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/203

Previously, the global cancer stem cells market was anticipated to garner a revenue of $956.6 million in 2020. However, in the present situation, i.e., in 2020, the market size is predicted to reach up to $982.5 million. Early therapy cannot remove or treat the tumor cells that are found in the body, and instead involves treatments that kill the tumor cells and improve better therapeutic longevity. The implementation of CSC therapy globally has a positive effect on the global cancer stem cells market.

According to our analysts, the global cancer stem cells market is projected to observe substantial growth in 2020 and will continue to grow at a significant growth rate after the end of the COVID-19 pandemic. In 2001, Gleevec was used to administer a genetic drug called chronic myelogenous leukemia (CML) for the treatment of rare cancer.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/203

Enhanced emphasis on customized diagnosis and strengthened cell-based research & development programs is predicted to broaden the application of CSC for the treatment of various kinds of cancer. Furthermore, CSCs are used to treat tumors of the nervous system, such as gliomas, medulloblastoma, and ependymomas. These factors are expected to fuel the demand expansion of cancer stem cells during the forecast period.

Besides, cumulative investments and rising advancements in the cancer stem cells are projected to unlock massive opportunities and thrust the growth of the global cancer stem cells market, post-COVID-19 pandemic.

Contact Us:

Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) + 91 (788) 802-9103 (India) +1 (917) 444-1262 (US) Toll Free : +1 -888-961-4454 Email:[emailprotected] LinkedIn:https://www.linkedin.com/company/research-dive Twitter:https://twitter.com/ResearchDive Facebook:https://www.facebook.com/Research-Dive Blog:https://www.researchdive.com/blog Follow us on:https://covid-19-market-insights.blogspot.com

Excerpt from:
What Is the Impact of COVID-19 on Cancer Stem Cells Market During Projected Period of 2020-2026? - Market Research Posts

Global Outlook for Cell Reprogramming and Direct Reprogramming Services and Products Market to 2030, with Company Profiles of Leading Players…

DUBLIN, July 31, 2020 /PRNewswire/ -- The "Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The 'Cell Reprogramming (iPSC Generation)/Direct Reprogramming Services and Products Market, 2020-2030' report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

In addition to other elements, the study includes:

One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030.

The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. CURRENT MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Allele Biotechnology 6.3. ALSTEM 6.4. Applied Biological Materials 6.5. Axol Bioscience 6.6. Creative Bioarray 6.7. DefiniGEN 6.8. FUJIFILM Cellular Dynamics International 6.9. Lonza 6.10. Mogrify 6.11. REPROCELL 6.12. Stemnovate 6.13. Thermo fisher Scientific

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

8. PARTNERSHIPS AND COLLABORATIONS

9. LIKELY PARTNERSHIP OPPORTUNITIES

10. MARKET FORECAST

11. EXECUTIVE INSIGHTS

12. CONCLUDING REMARKS

For more information about this report visit https://www.researchandmarkets.com/r/dywciv

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

See original here:
Global Outlook for Cell Reprogramming and Direct Reprogramming Services and Products Market to 2030, with Company Profiles of Leading Players...

BioLineRx to Report Second Quarter 2020 Results on August 6, 2020 – BioSpace

Management to hold a conference call at 10:00 a.m. EDT

TEL AVIV, Israel, July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US markets open.

The Company will host a conference call on Thursday, August 6, 2020 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-888-668-9141 from the U.S. or +972-3-918-0610 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until August 8, 2020; please dial +1-888-782-4291 from the U.S. or +972-3-925-5921 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Contact: Tim McCarthy LifeSci Advisors, LLC +1-212-915-2564 tim@lifesciadvisors.com

or

Moran Meir LifeSci Advisors, LLC +972-54-476-4945 moran@lifesciadvisors.com

View original content:http://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2020-results-on-august-6-2020-301103774.html

SOURCE BioLineRx Ltd.

Company Codes: Frankfurt:YP2A.F, NASDAQ-SMALL:BLRX, TelAviv:BLRX

See the original post here:
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020 - BioSpace

Animal Stem Cell Therapy Market to Witness a Pronounce Growth During 2025: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM – Owned

A recent report published by Research Reports Inc on the Animal Stem Cell Therapy market is a detailed assessment of the most important market dynamics.

Get Free Sample Copy of Animal Stem Cell Therapy Report 2020: http://www.researchreportsinc.com/report-sample/552373

(Use Corporate eMail ID So Immediately Accessible With Higher Priority.)

The Animal Stem Cell Therapy Market research report summaries various key players dominating the market. It includes several aspects covering the overview of key firms, their monetary summary, business tactics, and the recent advancements in these firms. Animal Stem Cell Therapy report offers a complete industry analysis. In this analysis, the end-users are provided with the market size, growth and value chain analysis. The Animal Stem Cell Therapy report represents a comprehensive view of the global Animal Stem Cell Therapy Market. It employs various methodological techniques such as five Porters analysis to provide a competitive outlook.

The Major Players Covered In This Report:

MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

The competition section of the Animal Stem Cell Therapy market features profiles of key players operating in the Animal Stem Cell Therapy market based on company shares, differential strategies, Animal Stem Cell Therapy product offerings, marketing approach, and company dashboard. Research studies have been conducted on Animal Stem Cell Therapy market size for the forecast period 2020 to 2025. The Animal Stem Cell Therapy market report offers a comprehensive evaluation of the business opportunities prevailing in the Animal Stem Cell Therapy market along with insights on the trend, market dynamics, Animal Stem Cell Therapy market size opportunity analysis, and Animal Stem Cell Therapy market competition.

The Animal Stem Cell Therapy report covers the following Types:

On the basis of applications, the market covers:

Get Discount on this Report: http://www.researchreportsinc.com/check-discount/552373

The research report includes the latest updates about the COVID-19 impact on the Animal Stem Cell Therapy market. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

The Animal Stem Cell Therapy Market report wraps:

The report also emphasizes the initiatives undertaken by the businesses operating within the market including product innovation, product launches, and technological development to assist their organization offer simpler products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

See original here:
Animal Stem Cell Therapy Market to Witness a Pronounce Growth During 2025: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM - Owned

Rheumatoid Arthritis Stem Cell Therapy Market Shares, Strategies and Forecast Worldwide, 2018 to 2028 Bulletin Line – Bulletin Line

Fact.MR, in its recently published market research report, provides an in-depth analysis of the Rheumatoid Arthritis Stem Cell Therapy market included the anticipated growth pattern of the market over the forecast period (2019-2029). A detailed assessment of the various micro and macro-economic factors that are likely to shape the course of the Rheumatoid Arthritis Stem Cell Therapy market over the next decade is enclosed in the report. The study suggests that the Rheumatoid Arthritis Stem Cell Therapy market is expected to register a CAGR growth of XX% over the forecast period primarily driven by factors including factor 1, factor 2, factor 3, and factor 4.

Further, the methodical and systematic approach adopted by the analysts while curating the report ensures that the data in the report is insightful, relevant, and a valuable tool for our clients to gain a competitive advantage in the current and future market landscape.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Competitive assessment

The competitive assessment included in the report throws light on the business strategies incorporated by leading market players operating in the Rheumatoid Arthritis Stem Cell Therapy market. The comprehensive study provides a birds eye view of the business operations of top-tier market players along with relevant graphs, figures, and tables.

Regional analysis

The regional analysis section touches upon the market scenario in the various geographies worldwide and the factors that are projected to influence the market dynamics in each region. The impact of the economic and political policies of different countries in each region is discussed in the report in detail.

End Use study

The report bifurcates the Rheumatoid Arthritis Stem Cell Therapy market on the basis of end-use and tracks the Y-o-Y growth of each end use segment.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Important questions answered in the report:

Why Choose Fact.MR?

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

See original here:
Rheumatoid Arthritis Stem Cell Therapy Market Shares, Strategies and Forecast Worldwide, 2018 to 2028 Bulletin Line - Bulletin Line

Arson at The Way Christian Center and The Shortage of Stem Cell Donors of Color – KPFA – 94.1FM

Davey D brings us audio from todays press conference held at The Way Christian Center in Berkeley Ca. Less than 12 hours after The Way Christian Center placed a Black Lives Matter banner, someone set fire to several trash cans positioned at the back of the church. The act of arson, damaged a portion of the building (see photos below) and has created fear and anger in the community.

Later we speak with Jess Tom and Carol Gillespie about treatment for blood-related cancers, the shortage of stem cell donors of color and the need to improve the registries. Seventy percent of patients wont have a match in their families and must find an unrelated donor. Patients are more likely to match donors who share the same ethnic background, but the lack of diversity on the Be The Match national registry makes it difficult for patients to find one. The Asian American Donor Program (AADP,

Guests:

Pastor Michael McBride (known as Pastor Mike) The fire was an act of terror, said Pastor Michael McBride, who leads the 48-year-old Way Christian Church.

Pastor Michael McBride is a native of San Francisco, CA. and has been active in ministry for almost 20 years. In June 2005, Pastor McBridelaunched a new ministry, The Way Christian Center in West Berkeley, where he presently serves as thePastor.

Carol Gillespie, Executive Director, Asian American Donor Program

Carol Gillespie is one of the original members of the Board of Directors for the Asian American Donor Program (AADP) when it was founded in 1989. She volunteered for AADP for3 years before accepting the position as Project Administrator in 1992. In 2002, Gillespie was selected as AADPs Executive Director and is currently serving in that position.

Jess Tom, Chef, Author, and TV Guest

Jess Tom is the sister of Andrew, who at 29 years old was living his dream and engaged to the love of his life. In May 2020 Andrew went to the doctor for swollen lymph nodes. A couple of days later, he was diagnosed withmixed phenotype acute leukemia (MPAL), a rare and aggressive form of leukemia. MPAL accounts for only 2-5% of all leukemias. The only way he can beat the illness is with a stem cell transplant.

In order to have a stem cell transplant, first a stem cell match for Andrew must be found. No one in Andrews family is a match. As being a match is genetically based, Andrews stem cell match will most likely be someone who is Chinese.Chinese donors only make up 0.7% of the national donor registry, leaving him with only a 43% chance of finding a perfect match.

Jess Tom has been working with the Asian American Donor Program, a nonprofit organization, to encourage Chinese Americans to register as potential stem cell donors. Sheis a chef and winner of season 14 ofFood Network Star. Jess Tom is a writer and food blogger living in Brooklyn.

She is the author ofFOOD WHORE: A Novel of Dining & Deceitpublished by William Morrow/HarperCollins. The paperback edition was released in 2015.FOOD WHORE, Jess first novel, merges her love of food and fiction.

You can find Jess on stage, online and on television, appearing on the Food Network, Good Morning America, the Today Show, and more.She has worked on initiatives with food trucks, restaurants, hospitality startups, and citywide culinary programs.

Read more:
Arson at The Way Christian Center and The Shortage of Stem Cell Donors of Color - KPFA - 94.1FM